These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31697304)

  • 1. Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity.
    Crouch ER; Kraker RT; Wallace DK; Holmes JM; Repka MX; Collinge JE; Bremer DL; Gray ME; Smith HA; Steinkuller PG;
    JAMA Ophthalmol; 2020 Jan; 138(1):14-20. PubMed ID: 31697304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.
    Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA;
    JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments.
    Wallace DK; Dean TW; Hartnett ME; Kong L; Smith LE; Hubbard GB; McGregor ML; Jordan CO; Mantagos IS; Bell EF; Kraker RT;
    Ophthalmology; 2018 Dec; 125(12):1961-1966. PubMed ID: 29887334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity.
    Wallace DK; Hercinovic A; Freedman SF; Crouch ER; Bhatt AR; Hartnett ME; Yang MB; Rogers DL; Hutchinson AK; Good WV; Repka MX; Li Z; Beck RW; Kraker RT; Cotter SA; Holmes JM;
    J AAPOS; 2023 Feb; 27(1):10.e1-10.e8. PubMed ID: 36681111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.
    Freedman SF; Hercinovic A; Wallace DK; Kraker RT; Li Z; Bhatt AR; Boente CS; Crouch ER; Hubbard GB; Rogers DL; VanderVeen D; Yang MB; Cheung NL; Cotter SA; Holmes JM;
    Ophthalmology; 2022 Oct; 129(10):1120-1128. PubMed ID: 35660415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser.
    Isaac M; Mireskandari K; Tehrani N
    J AAPOS; 2015 Apr; 19(2):140-4. PubMed ID: 25892041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity.
    Wallace DK; Kraker RT; Freedman SF; Crouch ER; Bhatt AR; Hartnett ME; Yang MB; Rogers DL; Hutchinson AK; VanderVeen DK; Haider KM; Siatkowski RM; Dean TW; Beck RW; Repka MX; Smith LE; Good WV; Kong L; Cotter SA; Holmes JM;
    JAMA Ophthalmol; 2020 Jun; 138(6):698-701. PubMed ID: 32324197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study.
    Wallace DK; Kraker RT; Freedman SF; Crouch ER; Hutchinson AK; Bhatt AR; Rogers DL; Yang MB; Haider KM; VanderVeen DK; Siatkowski RM; Dean TW; Beck RW; Repka MX; Smith LE; Good WV; Hartnett ME; Kong L; Holmes JM;
    JAMA Ophthalmol; 2017 Jun; 135(6):654-656. PubMed ID: 28448664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
    Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
    Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up.
    Martínez-Castellanos MA; Schwartz S; Hernández-Rojas ML; Kon-Jara VA; García-Aguirre G; Guerrero-Naranjo JL; Chan RV; Quiroz-Mercado H
    Retina; 2013 Feb; 33(2):329-38. PubMed ID: 23099498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
    Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
    Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants.
    ; Hartnett ME; Wallace DK; Dean TW; Li Z; Boente CS; Dosunmu EO; Freedman SF; Golden RP; Kong L; Prakalapakorn SG; Repka MX; Smith LE; Wang H; Kraker RT; Cotter SA; Holmes JM
    JAMA Ophthalmol; 2022 Apr; 140(4):337-344. PubMed ID: 35446359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurodevelopmental Outcomes after Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity: A Prospective Case-Control Study.
    Fan YY; Huang YS; Huang CY; Hsu JF; Shih CP; Hwang YS; Yao TC; Lai CC; Wu WC
    Ophthalmology; 2019 Nov; 126(11):1567-1577. PubMed ID: 30954553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refractive error outcomes after intravitreal ranibizumab for retinopathy of prematurity.
    Meng Q; Cheng Y; Wu X; Zhao D; Zhao M; Liang J
    Clin Exp Optom; 2020 Jul; 103(4):495-500. PubMed ID: 31802528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
    Toy BC; Schachar IH; Tan GS; Moshfeghi DM
    Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.
    Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
    Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.
    Kychenthal A; Dorta P
    Retina; 2010 Apr; 30(4 Suppl):S32-6. PubMed ID: 20224474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings.
    Lepore D; Quinn GE; Molle F; Orazi L; Baldascino A; Ji MH; Sammartino M; Sbaraglia F; Ricci D; Mercuri E
    Ophthalmology; 2018 Feb; 125(2):218-226. PubMed ID: 28867130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial.
    Marlow N; Stahl A; Lepore D; Fielder A; Reynolds JD; Zhu Q; Weisberger A; Stiehl DP; Fleck B;
    Lancet Child Adolesc Health; 2021 Oct; 5(10):698-707. PubMed ID: 34391532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.